Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Cancer Research

• Publication date

  2005-01-15

• Fields of study

  Medicine

• Identifiers
  PMID 15701892
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anastrozole versus tamoxifen as neoadjuvant therapy for oestrogen receptor-positive breast cancer in postmenopausal women: the IMPACT and PROACT trials

  2004cited by this paper
• Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study

  2004cited by this paper
• Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.

  2004cited by this paper
• Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.

  2003cited by this paper
• Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer.

  2003cited by this paper
• Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer

  2003cited by this paper
• Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.

  2002cited by this paper
• Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy.

  2002cited by this paper
• Ki67 protein: the immaculate deception?

  2002cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

  2002cited by this paper
• Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.

  2002influential reference
• Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen.

  2002cited by this paper
• Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.

  2001cited by this paper
• Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.

  2000cited by this paper
• Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma

  2000cited by this paper
• Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.

  1999cited by this paper
• Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Preoperative chemotherapy induces apoptosis in early breast cancer.

  1997cited by this paper
• Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.

  1995cited by this paper
• Apoptosis in breast cancer as related to histopathological characteristics and prognosis.

  1994cited by this paper
• Integrated control of cell proliferation and cell death by the c-myc oncogene.

  1994cited by this paper
• Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.

  1993cited by this paper
• Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro.

  1993cited by this paper
• Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation.

  1991cited by this paper

• Adjuvant endocrine therapy in high-risk HR-positive and HER2-negative early breast cancer

  2026cites this paper
• Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial

  2026cites this paper
• Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer

  2025cites this paper
• Mathematical and numerical tumour development modelling for personalised treatment planning

  2025cites this paper
• Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 2: Systemic Treatment

  2025cites this paper
• Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy.

  2025cites this paper
• Early Predictive Markers and Histopathological Response to Neoadjuvant Endocrine Therapy in Postmenopausal Patients with HR+/HER2− Early Breast Cancer

  2025cites this paper
• Preoperative hormone sensitivity test as a tool for personalizing systemic therapy in breast cancer patients

  2025cites this paper
• CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer

  2025cites this paper
• CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer

  2025cites this paper
• Efficacy of Presurgical Short-Term Endocrine Therapy During the Waiting Period for Surgery in Postmenopausal Hormone Receptor-Positive Breast Cancer

  2025influential citation
• Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II study

  2025cites this paper
• Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?

  2024cites this paper
• Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer

  2024cites this paper
• Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression

  2024cites this paper
• Envisioning Clinical Management of Breast Cancer: a Comprehensive Review.

  2024cites this paper
• A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study

  2024cites this paper
• Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer

  2024cites this paper
• Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives

  2024cites this paper
• Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

  2023cites this paper
• Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.

  2023cites this paper
• The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness

  2023cites this paper
• The immune microenvironment characterisation and dynamics in hormone receptor–positive breast cancer before and after neoadjuvant endocrine therapy

  2023cites this paper
• Which Patients Need Chemotherapy? From Pathological Risk Factors to Gene Signatures and Evaluation of Endocrine Response

  2023cites this paper
• Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

  2023cites this paper
• Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers

  2023cites this paper
• Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP

  2023cites this paper
• Effective Ki-67 Reduction by Pre-Surgery Short-Term Administration of Letrozole in (Hormone-Positive) Breast Cancer

  2023cites this paper
• Innovations and Challenges in Breast Cancer Care: A Review

  2023cites this paper
• Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer

  2022cites this paper
• Reduction in tumor grade and Ki-67 in postmenopausal patient with node-positive invasive ductal carcinoma following combination hormone replacement therapy cessation: a case report

  2022cites this paper
• Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.

  2022cites this paper
• Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study

  2022cites this paper
• Systemic therapy for early-stage breast cancer: learning from the past to build the future

  2022cites this paper
• Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial

  2022cites this paper
• What Is the Role of Neoadjuvant Endocrine Therapy for Breast Cancer?

  2022cites this paper
• Прогностическая и предиктивная значимость маркера Ki67 при раке молочной железы

  2022cites this paper
• Ki 67: a Promising Prognostic Marker in Early Breast Cancer—a Review Article

  2022cites this paper
• Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer

  2022cites this paper
• High SURF4 expression is associated with poor prognosis of breast cancer

  2022cites this paper
• The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study

  2022cites this paper
• Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

  2022cites this paper
• Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer

  2022cites this paper
• The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer

  2021cites this paper
• Magnetic resonance imaging radiomics signatures for predicting endocrine resistance in hormone receptor-positive non-metastatic breast cancer

  2021cites this paper
• IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women

  2021cites this paper
• TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer

  2021cites this paper
• 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

  2021cites this paper
• Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer

  2021cites this paper
• Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

  2021cites this paper
• Impact of Metformin on Cancer Biomarkers in Non-Diabetic Cancer Patients: A Systematic Review and Meta-Analysis of Clinical Trials

  2021cites this paper
• High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

  2021cites this paper
• ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer

  2021cites this paper
• Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis

  2021cites this paper
• The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment

  2021cites this paper
• Recent advances in neoadjuvant therapy for breast cancer

  2021cites this paper
• Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

  2021cites this paper
• Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art

  2021cites this paper
• Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy

  2021cites this paper
• External verification and improvement of the Neo-Bioscore staging system in a Chinese cohort

  2021cites this paper
• Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB)

  2021cites this paper
• Efficacy of EGFR Inhibitors and NSAIDs Against Basal Bladder Cancers in a Rat Model: Daily vs. Weekly Dosing, Combining EGFR Inhibitors with Naproxen, and Effects on RNA Expression

  2021cites this paper
• Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitors

  2021cites this paper
• The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis

  2020cites this paper
• Novel Targets and Biomarkers in Solid Tumors

  2020cites this paper
• Randomized Phase IIB Trial of the Lignan Secoisolariciresinol Diglucoside in Premenopausal Women at Increased Risk for Development of Breast Cancer

  2020cites this paper
• Empleo actual de la hormonoterapia neoadyuvante en cáncer de mama: resultados de una encuesta realizada en España

  2020cites this paper
• Implementing preoperative endocrine therapy in breast cancer.

  2020cites this paper
• A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.

  2020cites this paper
• Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial

  2020cites this paper
• Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group

  2020cites this paper
• Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

  2020cites this paper
• Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives

  2020cites this paper
• Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy

  2020cites this paper
• The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer

  2020cites this paper
• Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

  2019cites this paper
• Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors

  2019cites this paper
• Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers

  2019influential citation
• Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients

  2019cites this paper
• Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

  2019cites this paper
• Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor – Positive Early Breast Cancer

  2019cites this paper
• Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR

  2019cites this paper
• Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients

  2019cites this paper
• Primary Endocrine Therapy

  2019cites this paper
• Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment

  2019cites this paper
• Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

  2019cites this paper
• Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer

  2019cites this paper
• Title Clinical significance of the expression of autophagy-associated marker , beclin 1 , in breast cancer patients who

  2019cites this paper
• Title: Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically-Induced Cancers

  2019influential citation
• Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting

  2019cites this paper
• Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer (CBCSG‐036): A randomized, controlled, multicenter trial

  2019influential citation
• Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research

  2019cites this paper
• Predictive markers of endocrine response in breast cancer

  2018cites this paper
• Progress in adjuvant systemic therapy for breast cancer

  2018cites this paper
• The Potential for Individualization of Neoadjuvant Chemotherapy in Breast Cancer

  2018cites this paper
• Prognostic factors in breast cancer with a focus on the role of tumour proliferation

  2018cites this paper
• Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial

  2018cites this paper
• ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

  2018cites this paper
• Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling

  2018cites this paper
• Abemaciclib for the treatment of breast cancer

  2018cites this paper